Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma S.a.

Aventis Pharma Deutschland, Gmbh

Swen Hoelder

Karl Schoenafinger

Hans Matter

David William Will

Guenter Mueller

Martin Bossart

Anke Steinmetz

Ingrid Sassoon

Christine Delaisi

Gunter Muller

Cecile Combeau

Stefan Petry

Karl-Heinz Baringhaus

Didier Benard

Günter Müller

Cécile Combeau

Disclosed are compounds of Formula I wherein X is and R, R, A, B, D, E, Rare as defined herein useful for treating cancers.

Pyridazinone kinase inhibitors

Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, Rand Rare detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals.  These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

4-benzimidazol-2-ylpyridazin-3-one derivatives

The present invention relates to kinase inhibitor compounds and derivatives thereof as well as compositions comprising them consisting of the structure of formula I: Wherein R1, R2, A, B, D and E are defined herein. These 4-benzimidazol-2-ylpyridazin-3-ones and their derivatives and compositions comprising them are useful in the treatment of neurological disorders such as Alzheimers' disease, Parkinsons' disease, obesity, hypertension and the like. These pyridazinone derivatives particularly inhibit the metabolic activity of glycogen synthase kinase-3 &#x3b2; (GSK-3&#x3b2;) which is believed to cause the neurodegeneration that results in these diseases.

4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments

The present invention relates to pyridazinone compounds and their derivatives according to the general formula (I), with the substituents X, Rand Rdefined herein, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK-3&#x3b2; (glycogen synthase kinase-3&#x3b2;) which are useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovary syndrome and syndrome X or immunodeficiency.

Pyridazinone derivatives, methods for their production and their use as pharmaceuticals

Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, Rand Rare detailed in the description, as well as their physiologically acceptable salts and solvate, methods for producing these compounds and their use as pharmaceuticals.  These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

Pyridazinone derivatives

The invention relates to substituted and unsubstituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxides, 1,3-dihydrobenzo[1,2,5]thiadiazole 2,2-dioxides and 1,3-dihydro-benzo[c]isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.

Substituted an unsubstituted benzooxathiazoles and compounds derived therefrom

The invention relates to substituted and unsubstituted 3H-benzo&lsqb;1,2,3&rsqb;oxathiazole 2,2-dioxides, 1,3-dihydrobenzo&lsqb;1,2,5&rsqb;thiadiazole 2,2-dioxides and 1,3-dihydro-benzo&lsqb;c&rsqb;isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.

Growing community of inventors

Constance, Germany

Swen Hoelder